Cancer care network Oncology and Hematology Specialists has collaborated with Deep Lens to integrate the latter’s artificial-intelligence (AI)-based clinical trial matching platform, VIPER.

VIPER is designed using Deep Lens’ Cloud-based technology. It works by enabling, triaging and expediting the trial recruitment process.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based in New Jersey, US, Oncology and Hematology Specialists leverages distribution and technology services of Cardinal Health Specialty Solutions.

Cardinal Health launched a set of oncology-focused technology solutions called Navista TS and the VIPER platform is considered an important component of this offering.

Oncology and Hematology Specialists physician Fazal Bari said: “Our practice has always focused on adopting and providing the newest, most innovative approaches to cancer care to our patients, from cutting-edge therapeutics to supportive services and wellness events.

“VIPER will not only assist our staff in identifying the right trials for our patients, but the larger partnership with Deep Lens will assist in bringing more precision-based trials to our network, thereby giving more opportunities for our patients to access emerging new drugs in development.”

According to statistics, more than 15,000 cancer trials are actively enrolling patients, but participation is commonly as low as 3%. Patient enrolment is also impacted by limited site capacity and resources, Deep Lens said.

VIPER enables an automatic trial screening process. It matches patients to suitable trials by gathering and reviewing customised genomic data, electronic medical records and pathology data.

Deep Lens chief revenue officer Greg Andreola said: “We are confident that the inclusion of VIPER will not only help more cancer patients in Northern New Jersey access potentially life-changing new therapies, but it will position the cancer centre prominently as a leading clinical research institution.”

VIPER will be integrated into Oncology and Hematology Specialists’ electronic medical record, molecular data feeds, pathology and imaging feeds for automatic identification of eligible trial participants.

Earlier this month, Altru Health System entered a strategic alliance to adopt VIPER across its network.